Project Grant R01AI187287
Award Date 8/11/25
Completion Date 7/31/29
Dollars Obligated $3.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
- This federal Project Grant award of $545,563.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a study on the "Real-World Effectiveness of Maternal RSV Vaccination". The grant aims to evaluate the effectiveness of the world's first licensed RSV vaccine when administered to pregnant women between 32-36 weeks gestation, in preventing RSV-associated lower respiratory tract...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to comprehensively study the antibody response to novel respiratory syncytial virus (RSV) vaccines in a national observational cohort of immunosuppressed persons (ISPs). The $775,187 award to The Johns Hopkins University aims to better understand the impact of immunosuppression on antibody generation and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), will provide $189,276 to develop an agent-based modeling framework to characterize the burden and prevention strategies for respiratory syncytial virus (RSV) in the United States. The research project aims to establish a detailed understanding of RSV risk and natural history, and produce updated estimates of RSV...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), is supporting a $182,726 research initiative led by Dr. Sara Kim at Seattle Children's Hospital and the University of Washington. The project aims to understand the immune parameters associated with preventing Respiratory Syncytial Virus (RSV) lower respiratory tract infections in hematopoietic cell transplant recipients, a population at high...
- This $680,562 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the long-term lung epithelial alterations resulting from early-life respiratory syncytial virus (RSV) infection. The research aims to determine the mechanisms by which early-life RSV infection predisposes individuals to developing asthma later in life, focusing on the role of innate cytokines like IL-1β and IL-33 in driving...
- This $779,170 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to determine the burden of rhinoviruses (RVs) as a cause of severe respiratory illnesses leading to hospitalization in children. The 5-year study, starting on August 15, 2025, will create a longitudinal cohort of children in Madison, Wisconsin to identify circulating RVs and establish a nasal transcriptome to differentiate clinical RV...
- This $457,778 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a human microphysiological system (MPS) to investigate the peripheral nervous system (PNS) neurotropism of respiratory syncytial virus (RSV) and SARS-CoV-2. The research aims to elucidate the underlying mechanisms contributing to chronic neurological impairments associated with RSV and...
- This Project Grant award of $364,484, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel bronchodilators to alleviate respiratory distress in young children infected with Respiratory Syncytial Virus (RSV). The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will screen 8 clinically relevant soluble guanylate cyclase (SGC)...
- This Project Grant award of $565,834 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research will focus on understanding how RSV infection can cause epigenetic modifications in lung epithelial cells that lead to persistent changes in the lung's...
- The Project Grant award of $378,893 from the National Institute of Nursing Research (NINR), under the CFDA 93.361 Nursing Research program, will fund the integration of AI nowcasting models with digital communications to reduce respiratory syncytial virus (RSV) infections in rural areas. The project aims to build and operationalize a tailored spatio-temporal AI model to accurately predict RSV infection rates and deliver timely, targeted health messaging through trusted community channels like...